BEIJING, March 1, 2024 — CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced today that Peking Union Medical College Hospital (PUMCH) and CANbridge have officially announced the establishment of the “PUMCH-CANbridge Genetic Defect Rare Disease Innovation and Trans Base" ("Trans Base"). Going forward, the two parties will work together in innovative researches, from drug discovery to clinical translation.

Signing Ceremony of Strategic Cooperation Units of PUMCH Institute of Rare Disease Diagnosis and Treatment Innovation and Development

This collaboration of PUMCH and CANbridge provides a rare disease innovation and development platform to address significant scientific challenges related to rare diseases, accelerate the development of new drugs for genetic defect rare diseases, promote the development of a national rare disease industry ecosystem, and provide a foundation for breakthroughs in rare disease policies. PUMCH has rich experience in clinical translation and indication expansion, will provide great support in innovative research of this Translation Base. With its strong international experience in rare disease product development and commercialization, CANbridge will work closely with the PUMCH team to exploring various innovative attempts.

“On the 17^th  Rare Disease Day, we’d like to congratulate the official establishment of the PUMCH Institute of Rare Disease Diagnosis and Treatment Innovation and Development”  said James Xue, Ph.D., Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc. “PUMCH is responsible for research tasks for the National Key Laboratory of Complex, Severe and Rare Diseases, National Center for Translational Medicine, National Center for the National Cooperation Network in Diagnosis and Treatment for Rare Diseases, and National Quality Control Center for Rare Diseases, and has accumulated rich experience in the diagnosis and treatment of rare diseases and clinical research. We are honoured to collaborate with PUMCH in the establishment of our Translational Base . Going forward, both parties will leverage the platform  to conduct innovative researches from drug discovery to clinical translation. I look forward to explore innovative researches in drug development, application and accessibility for genetic-deficient rare diseases,  and bring  hopes to more rare disease patients and their families."

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with four approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Contact:

U.S. Investor Relations:

Chris Brinzey

ICR Westwicke

Chris.brinzey@westwicke.com

China Investor Relations

CANbridge Pharmaceuticals Inc.

ir@canbridgepharma.com

Media:

Deanne Eagle

Planet Communications

deanne@planetcommunications.nyc

917.837.5866